Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Hbc Immunology Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. Both matters are associated with 1 distinct examiner and 1 distinct art unit, indicating a concentrated examination path.
VARADARAJ, ARCHANA is the busiest examiner with 2 pending matters. Counsel can coordinate responses closely, compare the examiner’s treatment of related scientific issues, and preserve claim distinctions that depend on each application’s disclosure.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VARADARAJ, ARCHANA | 2 | 80.0% | +33.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832867 | MEDICINAL USES OF OLIGOPEPTIDES IN COMBINATION WITH AN ANTIANDROGEN | VARADARAJ, ARCHANA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832869 | UPREGULATION OF FERRITIN HEAVY CHAIN 1 EXPRESSION | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18832869 | UPREGULATION OF FERRITIN HEAVY CHAIN 1 EXPRESSION | VARADARAJ, ARCHANA | — |
| 18832867 | MEDICINAL USES OF OLIGOPEPTIDES IN COMBINATION WITH AN ANTIANDROGEN | VARADARAJ, ARCHANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18832869 | UPREGULATION OF FERRITIN HEAVY CHAIN 1 EXPRESSION | VARADARAJ, ARCHANA | 1658 | §101§103§112DP | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18832867 | MEDICINAL USES OF OLIGOPEPTIDES IN COMBINATION WITH AN ANTIANDROGEN | VARADARAJ, ARCHANA | 1658 | §103§112DP | Non-Final OA | — | Pending | Jul 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHbc Immunology Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Archana Varadaraj has the most, with 2 of Hbc Immunology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
